Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
Document Type
Article
Publication Date
9-2017
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.btre.2017.05.002
Funding Information
A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc).
Repository Citation
Kudrimoti, Mahesh; Curtis, Amarinthia; Azawi, Samar; Worden, Francis; Katz, Sanford; Adkins, Douglas; Bonomi, Marcelo; Scott, Zack; Elder, Jenna; Sonis, Stephen T.; Straube, Richard; and Donini, Oreola, "Dusquetide: Reduction in Oral Mucositis Associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients" (2017). Radiation Medicine Faculty Publications. 19.
https://uknowledge.uky.edu/radmed_facpub/19
Notes/Citation Information
Published in Biotechnology Reports, v. 15, p. 24-26.
© 2017 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).